Consensus Bicycle Therapeutics plc

Equities

BCYC

US0887861088

Real-time Estimate Cboe BZX Other stock markets 12:33:01 2024-04-16 pm EDT			5-day change	1st Jan Change
21.98 ^USD	+0.71%		-5.07%	+21.13%

Apr. 04	European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	MT
Apr. 03	Q32 Bio Appoints Lee Kalowski as President	CI

Evolution of the average Target Price on Bicycle Therapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

bc2e50cefd7d6.DMkJuc9s3rX5pYVcpHU3hrN5LTqbeJlnAZ1pdj0FN_0.WqVPgPcZjPqM0OEmxT5f1sIKFWntIdERMawwHgw2XLZk8WD4lSit15iSyA~48085472261559fadae1652572f3f20d

Analyst Recommendations on Bicycle Therapeutics plc

HC Wainwright Adjusts Bicycle Therapeutics Price Target to $55 From $57, Maintains Buy Rating	Feb. 21	MT
JMP Securities Cuts Bicycle Therapeutics Price Target to $32 From $44, Maintains Market Outperform Rating	Dec. 20	MT
Morgan Stanley Cuts Price Target on Bicycle Therapeutics to $40 From $42, Maintains Equal-Weight Rating	Nov. 03	MT
B. Riley Upgrades Bicycle Therapeutics to Buy From Neutral After Announced Alignment With US FDA on Phase 2/3 Registrational Trial for BT8009 for Metastatic Bladder Cancer; PT is $33	23-09-12	MT
Oppenheimer Adjusts Bicycle Therapeutics Price Target to $48 From $55, Maintains Outperform Rating	23-08-04	MT
JMP Securities Adjusts Price Target on Bicycle Therapeutics to $44 From $46, Maintains Outperform Rating	23-08-04	MT
Needham Adjusts Price Target on Bicycle Therapeutics to $46 From $48, Maintains Buy Rating	23-08-04	MT
Needham Adjusts Price Target on Bicycle Therapeutics to $64 From $67, Maintains Buy Rating	23-05-05	MT
Needham Adjusts Price Target on Bicycle Therapeutics to $67 From $72, Keeps Buy Rating	23-03-01	MT
EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target	23-01-05	MT
JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating	22-11-09	MT
Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating	22-09-12	MT
Bicycle Therapeutics Shares Rise After Cowen Initiates Coverage	22-08-31	MT
Cowen Initiates Coverage on Bicycle Therapeutics With Outperform Rating	22-08-31	MT
SVB Securities Lifts Price Target on Bicycle Therapeutics to $50 From $48, Keeps Outperform Rating	22-08-22	MT
HC Wainwright Lowers Bicycle Therapeutics Price Target to $57 From $65, Maintains Buy Rating	22-08-05	MT
Barclays Initiates Bicycle Therapeutics at Overweight With $30 Price Target	22-07-28	MT
Canaccord Genuity Assumes Bicycle Therapeutics at Buy with $60 Price Target	22-07-06	MT
Piper Sandler Lowers Bicycle Therapeutics' Price Target to $37 From $76, Maintains Overweight Rating	22-05-23	MT
B. Riley Downgrades Bicycle Therapeutics to Neutral from Buy, Finds Significantly More Risk in Bicycle Toxin Conjugate Platform; Lowers Price Target to $33 from $62	22-04-13	MT
Needham Adjusts Bicycle Therapeutics' Price Target to $75 from $85, Keeps Buy Rating	22-04-12	MT
Cantor Fitzgerald Assumes Bicycle Therapeutics at Overweight, $80 Price Target	22-04-07	MT
JMP Securities Lowers Bicycle Therapeutics Price Target to $70 From $85, Maintains Market Outperform Rating	22-03-03	MT
B. Riley Lowers Bicycle Therapeutics' Price Target to $62 from $72, Lowers Probability of Success of BT5528 in Model; Keeps Buy Rating	22-03-02	MT
Morgan Stanley Starts Bicycle Therapeutics at Equalweight With $60 Price Target	22-02-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.82 USD

Average target price

43.99 USD

Spread / Average Target

+101.59%

High Price Target

60 USD

Spread / Highest target

+174.98%

Low Price Target

30 USD

Spread / Lowest Target

+37.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bicycle Therapeutics plc

HC Wainwright
JMP Securities
Morgan Stanley
B. Riley
Oppenheimer
Needham & Co.
EF Hutton
Cowen
SVB Securities LLC
Barclays
Canaccord Genuity
Piper Sandler
Cantor Fitzgerald
SVB Leerink
Goldman Sachs

Ratings for Bicycle Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar